Drug Interactions between epoetin beta-methoxy polyethylene glycol and perindopril
This report displays the potential drug interactions for the following 2 drugs:
- epoetin beta-methoxy polyethylene glycol
- perindopril
Interactions between your drugs
perindopril epoetin beta-methoxy polyethylene glycol
Applies to: perindopril and epoetin beta-methoxy polyethylene glycol
Angiotensin-converting enzyme (ACE) inhibitors may interfere with the effects of both endogenous and exogenous erythropoietin, although data are conflicting with respect to the latter. A retrospective investigation of 43 dialysis patients treated with human recombinant erythropoietin for an average of ten months found that the group also receiving captopril had lower hemoglobin and hematocrit levels than the control group when given the same dosage of erythropoietin, and the difference was statistically significant. However, another retrospective investigation found no significant differences in the mean hematocrit level and erythropoietin dosage in 14 stable hemodialysis patients for up to 16 weeks before and 16 weeks after initiation of ACE inhibitor therapy. Previous studies have suggested that ACE inhibitors may interfere with hematopoiesis by decreasing the synthesis of endogenous erythropoietin or decreasing bone marrow production of red blood cells, but an actual pharmacokinetic or pharmacodynamic interaction with erythropoietin has not been reported. Until further data are available, it may be appropriate to monitor patients for potentially diminished hematopoietic response to recombinant erythropoietin therapy following the addition of an ACE inhibitor. It is not known if other erythropoiesis-stimulating agents are similarly affected.
References (2)
- Walter J (1993) "Does captopril decrease the effect of human recombinant erythropoietin in hemodialysis patients?" Nephrol Dial Transplant, 8, p. 1428-31
- Conlon PJ, Albers F, Butterly D, Schwab SJ (1994) "ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients." Nephrol Dial Transplant, 9, p. 1358
Drug and food interactions
perindopril food
Applies to: perindopril
GENERALLY AVOID: Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors. In some cases, affected patients were using a potassium-rich salt substitute. ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.
ADJUST DOSING INTERVAL: Administration with food decreased the biotransformation of perindopril to its active metabolite, perindoprilat, resulting in a decrease of perindoprilat bioavailability by 35% and a reduction in the plasma ACE inhibition curve of approximately 20%. When administered as part of a combination product with amlodipine and taken with food, perindopril and perindoprilat absorption rates have decreased by 18% and 14%, respectively, versus fasting. No effect of food on the extent of unmetabolized perindopril absorption has been observed.
MANAGEMENT: It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake. Particular attention should be paid to the potassium content of salt substitutes. Some authorities recommend administering perindopril before a meal, preferably in the morning. According to the prescribing information, the combination product containing perindopril and amlodipine may be taken with or without food.
References (7)
- Good CB, McDermott L (1995) "Diet and serum potassium in patients on ACE inhibitors." JAMA, 274, p. 538
- Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20
- (2024) "Product Information. Perindopril Erbumine (perindopril)." Aurobindo Pharma USA Inc
- (2023) "Product Information. Ag-Perindopril (perindopril)." Angita Pharma Inc.
- (2019) "Product Information. Prestalia (amlodipine-perindopril)." Adhera Therapeutics, Inc.
- (2024) "Product Information. Apo-Perindopril/Amlodipine (amlodipine-perindopril)." Apotex Inc
- (2022) "Product Information. Coversyl Plus HD (indapamide-perindopril)." Servier Canada Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.